{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"8.8","value":"7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"Overall survival is defined as the time from first dose to the date of death due to any cause. Participants still alive were censored at the last date known to be alive or at the data cut-off date, whichever was earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment to the data cut-off date of 01 September 2017; median time on follow-up in Phase 2 was 5.8 months (range 0.4 to 22.5 months).","title":"Phase 2 Dose Expansion: Kaplan-Meier Estimate of Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}